2
Clinical Trials associated with Anti-BCMA CAR-T (The First Affiliated Hospital,Zhejiang University School of Medicine) / Unknown statusPhase 2IIT B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma
It's a single arm, open label prospective study, in which the safety and efficacy of B Cell Maturation Antigen(BMCA)-targeted CAR-T thearpy are evaluated in refractory/relapsed multiple myeloma patients.
/ RecruitingNot ApplicableIIT Clinical and basic research on BCMA-CAR T cells in the treatment of multiple myeloma
Start Date31 Jul 2018 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-BCMA CAR-T (The First Affiliated Hospital,Zhejiang University School of Medicine)
100 Translational Medicine associated with Anti-BCMA CAR-T (The First Affiliated Hospital,Zhejiang University School of Medicine)
100 Patents (Medical) associated with Anti-BCMA CAR-T (The First Affiliated Hospital,Zhejiang University School of Medicine)
100 Deals associated with Anti-BCMA CAR-T (The First Affiliated Hospital,Zhejiang University School of Medicine)